Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proton Therapy | 19 | 2024 | 44 | 5.000 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 12 | 2024 | 216 | 2.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2023 | 200 | 1.830 |
Why?
|
| Protons | 7 | 2023 | 102 | 0.900 |
Why?
|
| Ependymoma | 2 | 2023 | 30 | 0.860 |
Why?
|
| Phantoms, Imaging | 7 | 2024 | 492 | 0.750 |
Why?
|
| Eye | 1 | 2017 | 113 | 0.500 |
Why?
|
| Thoracic Neoplasms | 1 | 2017 | 64 | 0.500 |
Why?
|
| Proprotein Convertase 1 | 4 | 2006 | 11 | 0.480 |
Why?
|
| Protein Precursors | 3 | 2006 | 133 | 0.460 |
Why?
|
| Movement | 2 | 2017 | 313 | 0.460 |
Why?
|
| Algorithms | 4 | 2019 | 2002 | 0.440 |
Why?
|
| Radiotherapy Dosage | 6 | 2023 | 479 | 0.410 |
Why?
|
| Organs at Risk | 5 | 2023 | 56 | 0.410 |
Why?
|
| Aspartic Acid Endopeptidases | 3 | 2003 | 69 | 0.410 |
Why?
|
| Positron-Emission Tomography | 4 | 2024 | 354 | 0.360 |
Why?
|
| Proinsulin | 2 | 2002 | 123 | 0.350 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 25 | 0.350 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2024 | 66 | 0.350 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2003 | 412 | 0.340 |
Why?
|
| Peptide Fragments | 3 | 2003 | 480 | 0.330 |
Why?
|
| Monte Carlo Method | 3 | 2023 | 194 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1110 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 228 | 0.270 |
Why?
|
| Breath Holding | 2 | 2017 | 26 | 0.260 |
Why?
|
| Intestinal Mucosa | 4 | 2016 | 834 | 0.260 |
Why?
|
| Peptide Hormones | 1 | 2006 | 30 | 0.240 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 2003 | 7 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 4 | 2019 | 1088 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2666 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1302 | 0.200 |
Why?
|
| Radiometry | 4 | 2024 | 64 | 0.190 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2002 | 13 | 0.190 |
Why?
|
| Dwarfism | 1 | 2002 | 13 | 0.180 |
Why?
|
| Glucagon | 1 | 2002 | 114 | 0.180 |
Why?
|
| Neoplasms | 2 | 2014 | 3334 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2018 | 325 | 0.150 |
Why?
|
| Papillomaviridae | 2 | 2018 | 184 | 0.150 |
Why?
|
| Islets of Langerhans | 1 | 2002 | 568 | 0.140 |
Why?
|
| Peptides | 1 | 2002 | 669 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2017 | 333 | 0.140 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 79 | 0.140 |
Why?
|
| Photons | 1 | 2018 | 52 | 0.140 |
Why?
|
| Humans | 18 | 2024 | 98080 | 0.130 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2017 | 18 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2016 | 2207 | 0.130 |
Why?
|
| Relative Biological Effectiveness | 1 | 2016 | 14 | 0.130 |
Why?
|
| Insulin | 1 | 2002 | 1225 | 0.130 |
Why?
|
| Uncertainty | 1 | 2017 | 81 | 0.120 |
Why?
|
| Esophagus | 1 | 2017 | 108 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 145 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 112 | 0.120 |
Why?
|
| Colon | 2 | 2010 | 562 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 310 | 0.120 |
Why?
|
| Respiration | 1 | 2017 | 274 | 0.110 |
Why?
|
| Simulation Training | 1 | 2017 | 118 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1028 | 0.110 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2014 | 43 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 152 | 0.110 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2014 | 16 | 0.110 |
Why?
|
| Autophagy | 1 | 2016 | 177 | 0.110 |
Why?
|
| Parotid Neoplasms | 1 | 2014 | 22 | 0.100 |
Why?
|
| Proprotein Convertases | 3 | 2003 | 27 | 0.100 |
Why?
|
| Consensus | 1 | 2016 | 315 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2016 | 256 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 2457 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 78 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2784 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 520 | 0.090 |
Why?
|
| Glioma | 1 | 2014 | 309 | 0.090 |
Why?
|
| Mice | 7 | 2016 | 12698 | 0.090 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 89 | 0.090 |
Why?
|
| Synchrotrons | 2 | 2022 | 33 | 0.080 |
Why?
|
| Microdissection | 1 | 2010 | 17 | 0.080 |
Why?
|
| Tight Junctions | 1 | 2011 | 158 | 0.080 |
Why?
|
| Lung | 1 | 2017 | 1407 | 0.080 |
Why?
|
| Metagenome | 1 | 2010 | 123 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 403 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 102 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2009 | 119 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 839 | 0.070 |
Why?
|
| Biodiversity | 1 | 2010 | 252 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 1211 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 750 | 0.060 |
Why?
|
| Animals | 8 | 2016 | 28894 | 0.060 |
Why?
|
| Ghrelin | 1 | 2006 | 31 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1173 | 0.060 |
Why?
|
| Cell Line | 4 | 2016 | 2483 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 2896 | 0.060 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 393 | 0.060 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 72 | 0.060 |
Why?
|
| DNA Repair | 2 | 2019 | 363 | 0.060 |
Why?
|
| Stomach | 1 | 2006 | 110 | 0.060 |
Why?
|
| Colitis | 1 | 2009 | 264 | 0.060 |
Why?
|
| Neurosecretory Systems | 2 | 2003 | 36 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 2005 | 0.060 |
Why?
|
| Time Factors | 2 | 2011 | 5567 | 0.060 |
Why?
|
| Scattering, Radiation | 2 | 2016 | 122 | 0.060 |
Why?
|
| Furin | 1 | 2003 | 11 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 18 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1836 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 2888 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3598 | 0.050 |
Why?
|
| Child | 1 | 2014 | 7681 | 0.050 |
Why?
|
| Proglucagon | 1 | 2002 | 5 | 0.050 |
Why?
|
| Corticosterone | 1 | 2002 | 35 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2002 | 72 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2002 | 96 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2002 | 124 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2002 | 65 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 118 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 1105 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 130 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 512 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 212 | 0.030 |
Why?
|
| Mitosis | 1 | 2018 | 152 | 0.030 |
Why?
|
| Gene Expression | 1 | 2002 | 1320 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2018 | 110 | 0.030 |
Why?
|
| Male | 3 | 2017 | 47076 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 279 | 0.030 |
Why?
|
| Bifidobacterium breve | 1 | 2016 | 2 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1604 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 3620 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 179 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 608 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 52 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 399 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 160 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 88 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 1014 | 0.030 |
Why?
|
| Adult | 1 | 2014 | 29539 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 425 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1752 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 709 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2080 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 801 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 163 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 10973 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 55 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 41 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1129 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2010 | 41 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1945 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1120 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 236 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2010 | 270 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 401 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2009 | 71 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 276 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 707 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 529 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 883 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1815 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 911 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2010 | 568 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 474 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1255 | 0.010 |
Why?
|
| Cytokines | 1 | 2009 | 889 | 0.010 |
Why?
|
| Phylogeny | 1 | 2010 | 1339 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 84 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 290 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2013 | 0.010 |
Why?
|
| Female | 2 | 2017 | 51536 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2003 | 165 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 142 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 273 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 581 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 310 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 334 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 426 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 2572 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 548 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 993 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 9711 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 1159 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 923 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 21758 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1391 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 29428 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 4071 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1807 | 0.010 |
Why?
|